Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN Lease liability

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept bmrn:OperatingAndFinanceLeaseLiabilityCurrent.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's lease liability.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's lease liability?
BioMarin Pharmaceuticals (BMRN) reported lease liability of $9.32M in Q1 2026.
How has BioMarin Pharmaceuticals's lease liability changed year-over-year?
BioMarin Pharmaceuticals's lease liability increased by 47.7% year-over-year, from $6.31M to $9.32M.
What is the long-term trend for BioMarin Pharmaceuticals's lease liability?
Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's lease liability has grown at a -4.6% compound annual growth rate (CAGR), from $10.46M to $8.69M.